Tumor-Associated Calcium Signal Transducer 2 (TROP2), also known as TACSTD2 and EGP-1, is a surface antigen found in numerous solid tumors. It has become a pivotal target for pharmaceutical giants spurring a race in drug development in the world. Currently, TROP2-targeting biopharmaceuticals are predominantly concentrated in the Antibody-Drug Conjugate (ADC). Based on incomplete statistics, there are 11 TROP2-targeting […]
Antibody-drug conjugates (ADCs) represent a promising class of targeted therapies in the fight against cancer. These innovative therapies aim to deliver small-molecule chemotherapy agents directly to cancer cells while sparing healthy ones. Since the approval of MYLOTARG in 2000, ADCs have become a vital category in the realm of cancer-targeted treatments, consisting of three key […]
In 2012, a young girl named Emily Whitehead, suffering from acute lymphoblastic leukemia, became the first child to undergo second-generation CD19 CAR-T cell therapy by Dr. Carl June, a scientist in Pennsylvania. Her successful treatment marked a historic milestone in the world of medicine. It brought “CAR-T cell immunotherapy,” a revolutionary approach in the fight […]